Gamma delta T cells have unique attributes that Adicet believes make them especially well-suited to be used for cancer therapy. The unique features of these cells combine adaptive (gamma delta TCR-mediated) and innate (NK-cell like) immunity to specifically recognize and eliminate tumor cells while sparing normal, healthy cells. Unlike alpha beta T cells, gamma delta T cells perform their tumor killing function in a MHC-independent manner and thus can be used in an allogeneic setting without the risk of causing Graft vs Host Disease (GvHD). Additionally, gamma delta T cells perform their immune surveillance by naturally homing to various tissues giving them a superior potential to alpha beta T cells to eradicate solid tumors in tissues. Adicet has demonstrated the cytotoxicity and anti-tumor activity of gamma delta T cells in vitro and in vivo in mouse models.
To date, the use of these cells has been limited because gamma delta T cells represent only a small fraction of the peripheral blood mononuclear cells (1-5%). Adicet has developed a proprietary and robust process to activate and expand different subsets of gamma delta T cells to numbers sufficient for utilization in the clinical setting.